Skip to main content

Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).

Publication ,  Conference
Plimack, ER; Hammers, HJ; Rini, BI; McDermott, DF; Redman, B; Kuzel, T; Harrison, MR; Vaishampayan, UN; Drabkin, HA; George, S; Logan, TF ...
Published in: Journal of Clinical Oncology
May 20, 2015

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2015

Volume

33

Issue

15_suppl

Start / End Page

4553 / 4553

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Plimack, E. R., Hammers, H. J., Rini, B. I., McDermott, D. F., Redman, B., Kuzel, T., … Motzer, R. (2015). Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). In Journal of Clinical Oncology (Vol. 33, pp. 4553–4553). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.4553
Plimack, Elizabeth R., Hans J. Hammers, Brian I. Rini, David F. McDermott, Bruce Redman, Timothy Kuzel, Michael Roger Harrison, et al. “Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 33:4553–4553. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.4553.
Plimack ER, Hammers HJ, Rini BI, McDermott DF, Redman B, Kuzel T, et al. Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 4553–4553.
Plimack, Elizabeth R., et al. “Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 4553–4553. Crossref, doi:10.1200/jco.2015.33.15_suppl.4553.
Plimack ER, Hammers HJ, Rini BI, McDermott DF, Redman B, Kuzel T, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Xu L-A, Waxman I, Motzer R. Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 4553–4553.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2015

Volume

33

Issue

15_suppl

Start / End Page

4553 / 4553

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences